BeiGene Investors
BeiGene is an innovative biotechnology company based in Cambridge, Massachusetts, founded in 2010 The company focuses on the discovery and development of molecularly targeted and immuno-oncology drug candidates for the treatment of cancer BeiGene has attracted significant investment, raising approximately $158,400,000 to support its research and development efforts The organization aims to advance the understanding of cancer biology and improve patient outcomes through its groundbreaking therapies With a commitment to scientific excellence, BeiGene is positioned as a leader in the biopharmaceutical industry
Founded Date:
2010
Last Funding Type:
Seed
Headquarters:
USA
Investors Number:
2
Technology:
Small Molecules
Employee Number:
1001-5000
Industry:
FemTech
Estimated Revenue:
$50M to $100M
Funding Status:
IPO
Investor Type:
Angel Groups
Total Funding:
£300K